GenSight will participate to the American Academy of Ophthalmology in San Francisco and will give oral presentations on its lead product candidates, GS010, to treat Leber’s Hereditary Optic Neuropathy (LHON) and GS030, to treat Retinitis Pigmentosa (RP)

GS010 – Leber’s Hereditary Optic Neuropathy (LHON) 

Oral presentation:   Efficacy of rAAV2/2-ND4 Gene Therapy for Leber Hereditary Optic Neuropathy: 48-Week Data From the Phase 3 RESCUE Trial

  • Presenting Author:  Dr. Patrick Yu-Wai Man, Senior Lecturer and Honorary Consultant Ophthalmologist at the University of Cambridge, Moorfields Eye Hospital, and the UCL Institute of Ophthalmology, London (UK)
  • Session Date/Time:  Sunday, October 13, 2019, 3:00 PM – 3:07 PM
  • Session Title:  Neuro-Ophthalmology Original Papers
  • Room:  South 152
  • Final abstract number:  PA021

GS030 – Optogenetics in Retinitis Pigmentosa

ePoster Theater Presentation:  The PIONEER Study:  A Phase 1/2 Optogenetic Retinal Gene Therapy Clinical Trial for Nonsyndromic RP

  • Presenting Author:  Dr Miss Simona Degli Esposti, Locum Research Consultant, NIHR Clinical Research Facility, Moorfields Eye Hospital NHS Foundation Trust, London (UK)
  • Session Date/Time:  Sunday, Oct 13, 2019, 5:10 PM
  • PT05 Session Topic:  Retina, Vitreous
  • Room:  South exhibition level
  • ePoster:  PO396